Stock screener

ABUS

Conviction 95HealthcareScan · Thu, Sep 24, 2026

Arbutus Biopharma Corp (ABUS) closed at $4.88 (+0.52%) on Sep 24, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 42, RS Rating 71, -6.6% from its 52-week high, +2.2% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

ABUS$4.88+0.52%
ResistanceSupportVol 14
63 bars
Vol MA14 5.66M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Arbutus Biopharma CorpPHARMACEUTICAL PREPARATIONSwww.arbutusbio.com ↗
Price4.88
Change+0.52%
Gap+0.52%
Rel volume2.60×
Avg volume5M
Avg $ vol25.17M
SMA 205.07
SMA 504.81
SMA 2004.54
Price vs 50+1.37%
Price vs 200+7.45%
MA stackbullish
50/200 cross—
Supertrendup · 4.77
RSI (14)42
MACD hist-0.05
MACD cross—
Stoch %K / %D16 / 10
ADX (14)23
+DI / −DI19 / 26
RSI divergence—
MACD divergence—
ATR %2.36%
ADR %1.74%
52w high5.22
52w low3.67
From 52w high-6.61%
Above 52w low+32.83%
New 52w highNo
SqueezeOff
Bollinger width6.83%
%B-0.07
Donchian pos16.47%
Donchian high5.23
Donchian low4.81
AVWAP (52w high)5.10
vs AVWAP high-4.45%
AVWAP (52w low)4.69
vs AVWAP low+4.03%
OBV trendFlat
Chaikin MF (20)-0.12
Today vs 20d2.60×
Avg vol (14d)5.66M
Avg vol (20d)5M
Avg $ vol (20d)25.17M
Market cap964.51M
RS Rating71 / 99
RS 3m (vs SPY)+6.05%
RS 6m (vs SPY)-9.20%
RS line new highNo
Trend template8/8
Technical rank62.4
1 week-3.85%
1 month-6.25%
3 months+10.54%
6 months+7.62%
1 year+9.30%
YTD+2.20%
P/E-28.79
P/B3.73
P/S68.49
P/FCF-24.33
EPS-0.1700
Div yield—
ROE-12.95%
ROA-12.23%
Debt/Eq0.00
Current81.42
EV/EBITDA—
Gross margin—
Net margin-237.88%
Rev growth128.21%
EPS growth52.09%
Price target—
Target upside—
Analyst rating—
Institutional75.65%
Ent. value945.34M
Revenue1.01M
Net income-5.14M
Gross profit—
Free cash flow-39.64M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out197.54M
Employees19
ListedThu, Jul 26, 2007
Free float156.47M
Float %79.5%
Short interest18.92M
Days to cover3.1d
Short volume77.7%
Squeeze score75 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.03
Last surprise—
Setup gradeA+
Conviction95 / 100
Pattern quality—
Tech rank62.4 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance5.34
Support4.70
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ABUS

All disclosures →
No recent disclosed trades by Congress in ABUS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ABUS

InsiderSideShares
Androski Lindsay
President and CEO · Common Shares · 2026-09-18
Exercise116.41K
Androski Lindsay
President and CEO · Common Shares · 2026-09-18
Exercise10.46K
Androski Lindsay
President and CEO · Common Shares · 2026-09-18
Tax82.53K
Androski Lindsay
President and CEO · Stock Option (Right to Buy) · 2026-09-18
Exercise116.41K
Androski Lindsay
President and CEO · Stock Option (Right to Buy) · 2026-09-18
Exercise10.46K
Beardsley Robert A
Director · Common Shares · 2026-09-18
Exercise52.53K
Beardsley Robert A
Director · Common Shares · 2026-09-18
Exercise78.8K
Beardsley Robert A
Director · Common Shares · 2026-09-18
Tax99.06K
Beardsley Robert A
Director · Stock Option (Right to Buy) · 2026-09-18
Exercise52.53K
Beardsley Robert A
Director · Stock Option (Right to Buy) · 2026-09-18
Exercise78.8K

SEC filings

EDGAR filings in ABUS · 8 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.